MedTrace Logo

Prognostic and Predictive Markers of Treatment Response in Patients With PAC.

NCT05776342 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 4050

Last updated 2025-03-25

No results posted yet for this study

Summary

The objective of this study is to identify prognosis and predictive markers of response to treatments (surgery, chemotherapy,...) in patients with pancreatic adenocarcinoma. The effectiveness and tolerance of these treatments in current practice is also evaluated.

Conditions

  • Pancreatic Adenocarcinoma

Sponsors & Collaborators

  • GERCOR - Multidisciplinary Oncology Cooperative Group

    lead OTHER

Principal Investigators

  • Angelique VIENOT, MD · CHRU de Besançon - Institut Régional Fédératif du Cancer (IRFC) de Franche-Comté

  • Anthony Turpin, MD · Hôpital Claude-Huriez

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-01-01
Primary Completion
2030-12-31
Completion
2031-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05776342 on ClinicalTrials.gov